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Objectives: We assessed the effects of thoracic endo-
vascular aortic repair (TEVAR) rehearsal with an endovas-
cular surgical simulator in surgical trainees at different
levels in training.
Methods: Twelve trainees in three cohorts (student,
postgraduate year [PGY]1-3, and PGY 4-7) were oriented
to using the Simbionix AngioMentor simulator over four
sessions. Likert scale qualitative analysis evaluated partici-
pant proﬁciency. Analysis of data included one-way analysis
of variance and paired t-tests.
Results: All groups had reduction of total procedure
time (mean 537 6 148 seconds vs 269 6 66 seconds, ﬁrst
session vs fourth; conﬁdence interval [CI], 195-341 seconds;
P < .05) and ﬂuoroscopy time (201 6 74 vs 110 6 37 sec-
onds; CI, 51-132 seconds; P < .05) with case progression.
Procedure time signiﬁcantly decreased in students (551 6
84 vs 313 6 65 seconds; CI 189-287 seconds; P < .05)
and PGY 1-3 (591 6 149 vs 264 6 29 seconds; CI, 113-
541 seconds;P< .02) had a signiﬁcant decrease in procedure
time. Fluoroscopy times were brief overall between individ-
uals and groups and did not change signiﬁcantly with case
progression. Participants acquired proﬁciency after a few
runs in almost every step of the procedure. Endograft sizing
appeared to be the most challenging task by qualitative anal-
ysis. PGY 4-7 trainees had higher technical scores, but this
was not statistically signiﬁcant.
Conclusions: Practice on endovascular surgical simula-
tors can reduce overall procedure and ﬂuoroscopy time,independent of trainee skill level or experience. Endovascu-
lar simulators can be effective tools in residency training and
maintenance of proﬁciency. Further studies are needed to
compare simulator performance with outcomes in real cases.
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Objectives: To evaluate the long-term (up to 24
months) outcome of stenting in TASC A and B and
TASC C and D iliac lesions in a controlled setting.
Methods: The BRAVISSIMO study is a prospective,
nonrandomized, multicenter, multinational, monitored
trial including 325 patients with aortoiliac lesions. The
end point is the primary patency at 24 months, deﬁned
as a target lesion without a hemodynamically signiﬁcant
stenosis on duplex ultrasound imaging (>50%, systolic ve-
locity ratio >2.0). A separate analysis for TASC A and B vs
TASC C and D population is performed.
Results: Between July 2009 and September 2010,
190 patients with TASC A or B and 135 patients with
TASC C or D aortoiliac lesions were included. The demo-
graphic data were comparable for the TASC A/B cohort
and the TASC C/D cohort. Technical success was 100%.
Signiﬁcantly more balloon-expandable stents were
deployed in TASC A and B lesions, and considerably
more self-expanding stents were placed in TASC C and
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months for the total population was 87.9% (88.0% for
TASC A, 88.5% for TASC B, 91.9% for TASC C, and
83.1% for TASC D, no statistically signiﬁcant difference
was shown when comparing these groups). The 24-
month primary patency rates were 92.1% for patients
treated with the self-expanding stent, 85.2% for patients
treated with the balloon-expandable stent, and 75.3%
for patients treated with a combination of both stents
(P ¼ .06). Univariate and multivariable regression ana-
lyses using Cox proportional hazards model identiﬁed
only kissing stent conﬁguration (P ¼ .0012) and obesity
(P ¼ .0109) as independent predictors of restenosis
(primary patency failure). Interestingly, because all
TASC groups enjoyed high levels of patency, neither
TASC category nor lesion length was predictive of
restenosis.
Conclusions: The 24-month data from this large, pro-
spective, multi-center study conﬁrm that endovascular
therapy may be considered the preferred ﬁrst-line treat-
ment option of aorto-iliac lesions, irrespectively of TASC
lesion category.
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Objectives: Open (OPAR) and endovascular (EPAR)
repair are both used to treat popliteal artery aneurysms
(PAA). We assessed outcomes of both modalities in the
treatment of asymptomatic PAA.
Methods: VQI databases (2010-2013) were queried
for patients undergoing asymptomatic PAA repair using
OPAR and EPAR. The groups were compared with
respect to demographics, medical history, and procedural
characteristics. Outcomes included major adverse limb
events (MALE), MALE and postoperative death
(MALE-POD), popliteal artery patency loss, and length
of stay (LOS). Proportional hazard Cox regression was
used to compare the outcomes across the treatment groups
and multivariate regression with backward elimination
procedure (a ¼ .5) was used to construct parsimonious
models.
Results: We identiﬁed 390 patients (221 OPAR, 169
EPAR). Preoperative comorbidities were similar between
the two groups, except for a higher rate of congestive
heart failure (11.8% vs 5.9%, P ¼ .043) and chronic
obstructive pulmonary disease (19.5% vs 11.8%, P ¼
.045) in the EPAR group. No in-hospital mortality was
observed. LOS was longer in the OPAR group(3.8 6 2.5 vs 1.4 6 1.9 days; P < .001). OPAR was asso-
ciated with lower hazard of MALE (0.35; 95% conﬁdence
interval [CI], 0.14-0.86), MALE-POD (0.28; 95% CI,
0.13-0.63), and popliteal artery patency loss (0.35; 95%
CI, 0.16-0.75). OPAR patients had a signiﬁcantly better
MALE-free survival (Fig).
Conclusions: This retrospective analysis suggests that
OPAR is associated with better outcomes than EPAR. Ul-
timately, the ongoing, adequately powered open vs endo-
vascular repair of PAA (OVERPAR) trial will deﬁnitively
compare these procedures.
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Objectives: The use of drug-eluting balloons
(DEBs) in treating de novo arteriosclerotic lesions is
well established. However, the effectiveness of this tech-
nology in femoropopliteal restenosis has to be demon-
strated. The purpose of the study was to assess the
efﬁcacy of paclitaxel-DEB in restenotic (stented ¼ ISR
and nonstented) vs de novo stenotic femoropopliteal
arteries.
Methods: Patients undergoing femoropopliteal
endovascular intervention with DEB for restenosis (RE)
or de novo stenosis (DN) were prospectively enrolled.
Excluded were patients with additional atherectomy.
Clinical parameters (age, risk, risk factors) were compara-
ble within the groups apart from the treated lesion
lengths (RE, 130 6 65 mm; DN, 115 6 71 mm; P ¼
.041). Primary end point was the primary patency (PP)
rate at 12 months. Secondary end points were secondary
sustained clinical improvement measured by Rutherford
classiﬁcation and clinically driven target lesion revascular-
ization (TLR).
